Shexiang Baoxin pill
Phase 3Small molecule
Shexiang Baoxin pill is one of 46 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
75 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Brilinta
AstraZenecaApproved
Plavix
SanofiApproved
Repatha
AmgenApproved
Bayer Aspirin
BayerApproved
Radicava
ShionogiApproved
Praluent
RegeneronApproved
Zebeta
TevaApproved
Onglyza
AstraZenecaApproved
Neoral
NovartisApproved
Effient
CCosette Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Shexiang Baoxin pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details